JP2016520594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520594A5 JP2016520594A5 JP2016515131A JP2016515131A JP2016520594A5 JP 2016520594 A5 JP2016520594 A5 JP 2016520594A5 JP 2016515131 A JP2016515131 A JP 2016515131A JP 2016515131 A JP2016515131 A JP 2016515131A JP 2016520594 A5 JP2016520594 A5 JP 2016520594A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- composition
- combination
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826692P | 2013-05-23 | 2013-05-23 | |
| US61/826,692 | 2013-05-23 | ||
| PCT/US2014/039437 WO2014190316A1 (en) | 2013-05-23 | 2014-05-23 | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520594A JP2016520594A (ja) | 2016-07-14 |
| JP2016520594A5 true JP2016520594A5 (https=) | 2017-06-29 |
| JP6587609B2 JP6587609B2 (ja) | 2019-10-09 |
Family
ID=50983195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515131A Active JP6587609B2 (ja) | 2013-05-23 | 2014-05-23 | 強皮症治療のための抗ｃｃｌ２及び抗ｌｏｘｌ２併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11059906B2 (https=) |
| EP (1) | EP2999484B1 (https=) |
| JP (1) | JP6587609B2 (https=) |
| CN (1) | CN105358175B (https=) |
| AU (2) | AU2014268316B2 (https=) |
| BR (1) | BR112015029300A2 (https=) |
| CA (1) | CA2912443A1 (https=) |
| EA (1) | EA201591993A1 (https=) |
| HK (1) | HK1224174A1 (https=) |
| MX (1) | MX371412B (https=) |
| WO (1) | WO2014190316A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3458157A4 (en) * | 2016-05-19 | 2020-05-27 | Momenta Pharmaceuticals, Inc. | METHOD FOR TREATING DISEASES RELATING TO FIBROSE AND SYSTEMIC Sclerosis |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CN107794267B (zh) * | 2017-03-14 | 2021-03-26 | 湖南大学 | 一种靶向pd1-pdl1的双特异性核酸适体及其衍生物 |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| KR20210151945A (ko) | 2019-04-12 | 2021-12-14 | 립타이드 바이오사이언스, 인코포레이티드 | 대식세포 활성을 조정하기 위한 방법 |
| CN110767262B (zh) * | 2019-09-18 | 2021-02-26 | 复旦大学 | 一种基于结构的核酸适配体优化设计方法 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| AU2020403913B2 (en) | 2019-12-18 | 2024-10-10 | F. Hoffmann-La Roche Ag | Bispecific anti-CCL2 antibodies |
| AU2022295067A1 (en) * | 2021-06-18 | 2023-12-21 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
| WO2023097111A2 (en) * | 2021-11-29 | 2023-06-01 | Riptide Bioscience, Inc. | Methods and compositions for treating calcinosis associated conditions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| WO1994008038A1 (en) | 1992-10-02 | 1994-04-14 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020025317A1 (en) | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
| AR037456A1 (es) * | 2001-11-30 | 2004-11-10 | Biogen Inc | Anticuerpos contra proteinas quimiotacticas monocitarias |
| ES2700141T3 (es) * | 2007-08-02 | 2019-02-14 | Gilead Biologics Inc | Anticuerpos inhibidores LOXL2 y usos de los mismos |
| EP2470671B1 (en) | 2009-08-28 | 2014-12-24 | Regeneron Pharmaceuticals, Inc. | Antikine antibodies that bind to multiple cc chemokines |
| BR112012019693A2 (pt) * | 2010-02-04 | 2017-06-20 | Gilead Biologics Inc | anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles. |
| US20150158942A1 (en) * | 2012-05-22 | 2015-06-11 | Shire Human Genetic Therapies, Inc. | Anti-ccl2 antibodies for treatment of scleroderma |
-
2014
- 2014-05-23 AU AU2014268316A patent/AU2014268316B2/en active Active
- 2014-05-23 EA EA201591993A patent/EA201591993A1/ru unknown
- 2014-05-23 CN CN201480036627.0A patent/CN105358175B/zh active Active
- 2014-05-23 HK HK16109679.1A patent/HK1224174A1/zh unknown
- 2014-05-23 EP EP14732752.2A patent/EP2999484B1/en active Active
- 2014-05-23 WO PCT/US2014/039437 patent/WO2014190316A1/en not_active Ceased
- 2014-05-23 MX MX2015016054A patent/MX371412B/es active IP Right Grant
- 2014-05-23 JP JP2016515131A patent/JP6587609B2/ja active Active
- 2014-05-23 US US14/893,486 patent/US11059906B2/en active Active
- 2014-05-23 CA CA2912443A patent/CA2912443A1/en not_active Abandoned
- 2014-05-23 BR BR112015029300A patent/BR112015029300A2/pt not_active Application Discontinuation
-
2019
- 2019-09-24 AU AU2019236656A patent/AU2019236656A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520594A5 (https=) | ||
| JP2017518258A5 (https=) | ||
| JP2016523235A5 (https=) | ||
| JP2014205674A5 (https=) | ||
| JP2021502984A5 (https=) | ||
| JP2016529229A5 (https=) | ||
| JP2017113019A5 (https=) | ||
| WO2017184619A3 (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| JP2016502515A5 (https=) | ||
| JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| JP2018504907A5 (https=) | ||
| JP2017531427A5 (https=) | ||
| JP2017113028A5 (https=) | ||
| JP2016183160A5 (https=) | ||
| JP2014500009A5 (https=) | ||
| JP2018510151A5 (https=) | ||
| MX2025002470A (es) | Combinaciones de anticuerpos anti-c5 y usos de las mismas | |
| MY163133A (en) | Humanized il-25 antibodies | |
| NZ758300A (en) | Human anti-semaphorin 4d antibody | |
| JP2021500874A5 (https=) | ||
| JP2012530487A5 (https=) | ||
| JP2017014254A5 (https=) | ||
| JP2016520595A5 (https=) | ||
| WO2018071822A3 (en) | Antibodies that bind zika virus envelope protein and uses thereof |